Kim Noonan on the Challenges of Treating Patients With Myeloma

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.